Clinical trial

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

NCT02648724

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-03-01

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2016-03-01Date precision: month

Registry last updated2022-06-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Oncologyunresolved

MET Gene Amplificationunresolved

NSCLCunresolved

MET Gene Mutationunresolved

Non Small Cell Lung Cancerunresolved

Interventions

Sym015DRUG

Sponsors & collaborators

Symphogen A/Slead sponsor

Mapped research locations

SeoulSouth Korea5 BostonMassachusetts, United States2 TaipeiTaiwan2 TaichungTaiwan2 HoustonTexas, United States1 ChicagoIllinois, United States1 DallasTexas, United States1 San AntonioTexas, United States1 MadridSpain1 ClevelandOhio, United States1 IndianapolisIndiana, United States1 AuroraColorado, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02648724 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.